10-K Filing

ENZON PHARMACEUTICALS, INC. CIK: 727510 FY 2021

Filing Information

Form Type	10-K
Accession Number	`0001410578-22-000226`
Period End Date	20211231
Filing Date	20220225
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	enzn-20211231x10k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 45 Income Statement 30 Cash Flow Statement 26 Stockholders Equity 11

Balance Sheet 45 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$47.64M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$48.14M	USD	Point-in-time
Royalty receivable	`MilestoneReceivableOnRoyaltiesCurrent`	$28.00K	USD	Point-in-time
Royalty receivable	`MilestoneReceivableOnRoyaltiesCurrent`	$31.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$85.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$59.00K	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Total assets (all current)	`Assets`	$48.23M	USD	Point-in-time
Total assets (all current)	`Assets`	$47.75M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	2.96M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	2.96M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$302.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$331.00K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$72.00K	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$110.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$403.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$412.00K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	170.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	170.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.21M	shares	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.21M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.21M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.21M	shares	Point-in-time
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at December 31, 2021 and 2020	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at December 31, 2021 and 2020	`PreferredStockValue`	-	USD	Point-in-time
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at December 31, 2021 and 2020	`CommonStockValue`	$742.00K	USD	Point-in-time
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at December 31, 2021 and 2020	`CommonStockValue`	$742.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$75.98M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$78.01M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-71.39M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-71.86M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.05M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.36M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.87M	USD	Point-in-time
Total liabilities, mezzanine equity and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$47.75M	USD	Point-in-time
Total liabilities, mezzanine equity and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$48.23M	USD	Point-in-time

Income Statement 30 line items

Line Item	Tag	Value	Unit	Period
Royalties and milestones, net	`RoyaltyRevenueAndMilestones`	$701.00K	USD	Annual
Royalties and milestones, net	`RoyaltyRevenueAndMilestones`	$52.00K	USD	Annual
Total revenues	`Revenues`	$52.00K	USD	Annual
Total revenues	`Revenues`	$701.00K	USD	Annual
General and administrative	`OtherGeneralAndAdministrativeExpense`	$1.17M	USD	Annual
General and administrative	`OtherGeneralAndAdministrativeExpense`	$1.36M	USD	Annual
Total operating expenses	`OperatingExpenses`	$1.17M	USD	Annual
Total operating expenses	`OperatingExpenses`	$1.36M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-469.00K	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-1.30M	USD	Annual
Other income	`OtherNonoperatingIncome`	$1.00K	USD	Annual
Other income	`OtherNonoperatingIncome`	$7.00K	USD	Annual
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.30M	USD	Annual
Loss before income tax expense	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-462.00K	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$7.00K	USD	Annual
Income tax expense	`IncomeTaxExpenseBenefit`	$7.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-1.31M	USD	Annual
Net loss	`NetIncomeLoss`	$-469.00K	USD	Annual
Dividends on Series C preferred stock	`PreferredStockDividendsIncomeStatementImpact`	$2.02M	USD	Annual
Dividends on Series C preferred stock	`PreferredStockDividendsIncomeStatementImpact`	$460.00K	USD	Annual
Net loss available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-2.49M	USD	Annual
Net loss available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-1.77M	USD	Annual
Basic loss per share	`EarningsPerShareBasic`	$-0.03	USD	Annual
Basic loss per share	`EarningsPerShareBasic`	$-0.03	USD	Annual
Diluted loss per share	`EarningsPerShareDiluted`	$-0.03	USD	Annual
Diluted loss per share	`EarningsPerShareDiluted`	$-0.03	USD	Annual
Weighted-average number of common shares outstanding - Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	51,100.00	shares	Annual
Weighted-average number of common shares outstanding - Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	74,215.00	shares	Annual
Weighted-average number of common shares outstanding - Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	74,215.00	shares	Annual
Weighted-average number of common shares outstanding - Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	51,100.00	shares	Annual

Cash Flow Statement 26 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-1.31M	USD	Annual
Net loss	`NetIncomeLoss`	$-469.00K	USD	Annual
Decrease (increase) in other current assets and accounts receivable	`IncreaseDecreaseInOtherOperatingAssets`	$23.00K	USD	Annual
Decrease (increase) in other current assets and accounts receivable	`IncreaseDecreaseInOtherOperatingAssets`	$28.00K	USD	Annual
Decrease in refundable tax credit receivable	`IncreaseDecreaseInLongTermReceivablesCurrent`	-	USD	Annual
Decrease in refundable tax credit receivable	`IncreaseDecreaseInLongTermReceivablesCurrent`	$-970.00K	USD	Annual
Increase (decrease) in accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$-22.00K	USD	Annual
Increase (decrease) in accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$29.00K	USD	Annual
(Decrease) increase in accrued expenses and other current liabilities	`IncreaseDecreaseInOtherAccruedLiabilities`	$-38.00K	USD	Annual
(Decrease) increase in accrued expenses and other current liabilities	`IncreaseDecreaseInOtherAccruedLiabilities`	$11.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-501.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-380.00K	USD	Annual
Payment of offering costs	`PaymentsOfStockIssuanceCosts`	$524.00K	USD	Annual
Payment of offering costs	`PaymentsOfStockIssuanceCosts`	-	USD	Annual
Proceeds from rights offering	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from rights offering	`ProceedsFromIssuanceOfCommonStock`	$43.60M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$43.08M	USD	Annual
Net (decrease) increase in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-501.00K	USD	Annual
Net (decrease) increase in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$42.70M	USD	Annual
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.45M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$48.14M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.64M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.45M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$48.14M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.64M	USD	Point-in-time

Stockholders Equity 11 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$6.05M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.36M	USD	Point-in-time
Balance	`StockholdersEquity`	$4.87M	USD	Point-in-time
Net loss	`NetIncomeLoss`	$-1.31M	USD	Annual
Net loss	`NetIncomeLoss`	$-469.00K	USD	Annual
Preferred stock dividend accumulation	`DividendsCommonStockStock`	$460.00K	USD	Annual
Preferred stock dividend accumulation	`DividendsCommonStockStock`	$2.02M	USD	Annual
Rights offering, proceeds net of expenses	`StockIssuedDuringPeriodValueNewIssues`	$3.08M	USD	Annual
Balance	`StockholdersEquity`	$6.05M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.36M	USD	Point-in-time
Balance	`StockholdersEquity`	$4.87M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.